What type of interactions should be monitored when prescribing Tekturna?

When prescribing Tekturna, it is essential to monitor interactions with cyclosporine and itraconazole. Tekturna, also known as aliskiren, is a direct renin inhibitor used to manage hypertension. It is primarily metabolized by the liver via the CYP3A4 enzyme pathway, making it susceptible to drug interactions that can alter its effectiveness or toxicity.

Cyclosporine is an immunosuppressant that can increase the serum levels of Tekturna by inhibiting its metabolism, potentially leading to an increased risk of side effects. Similarly, itraconazole, which is an antifungal medication, can also interfere with the metabolism of Tekturna through the same CYP3A4 pathway. Therefore, concurrent use of these medications requires careful consideration and monitoring due to the potential for enhanced effects of Tekturna.

Monitoring these interactions is crucial to ensure patient safety and the efficacy of the treatment plan. Proper management of these interactions can help avoid complications such as hypotension or other adverse reactions associated with increased plasma concentrations of Tekturna.